Background Patients with metastatic renal cell carcinoma (mRCC) treated with targeted
systemic therapies have demonstrated favourable outcomes in randomised controlled trials …

Background For patients with metastatic renal cell carcinoma (mRCC), targeted therapies
have entered the market since 2006. The aims of this study were to evaluate the uptake and …

Background New targeted therapeutics approved for metastatic renal cell carcinoma
(mRCC) offer multiple options in each line of therapy; however, there are few prospective …

Introduction The current treatment of metastatic renal cell carcinoma (mRCC) revolves
around targeted agents, which have resulted in a median overall survival of 22 to 26 months …

Abstract Introduction: The Metastatic Renal Cell Carcinoma (MaRCC) Registry provides
prospective data on real-world treatment patterns and outcomes in patients with metastatic …

AIM: Patterns of care for metastatic renal cell carcinomas (mRCC) have seen tremendous
reform in the last decade. Here, we present our pattern of care in second-line targeted …

Context In the last decade, there has been a proliferation of treatment options for metastatic
renal cell carcinoma (mRCC). However, direct comparative data are lacking for most of …

Aim To evaluate the implementation of targeted therapy on overall survival (OS) in a
complete national cohort of patients with metastatic renal cell carcinoma (mRCC). Methods …

Background Limited information on real-world treatment patterns of targeted agents for
metastatic renal cell carcinoma (mRCC) is available to inform their use in clinical practice …

Background It is well known that patient characteristics and survival outcomes in
randomized trials may not necessarily be similar to those in real-life clinical practice. The …